January 8th, 2008, by Digital Davo | accutane, macrolides, papules & pustules, steroids
One often asked question by newly diagnosed sufferers is `can you get rosacea on areas other than your face’. The usual answer is no; you normally only see rosacea symptoms on the flushing zone areas in the central areas of your face. This paper slightly dispels this idea with a case report about one patient who had rosacea lesions on his arm, and upper chest …
February 20th, 2007, by Digital Davo | accutane
This AAD Poster Session shows that the study of Rambazole is continuing, this time dosage and side effects are being investigated. Tolerability, safety, and pharmacokinetics of single and multiple oral dosages of R115866 in healthy volunteers, Marina Cools, PhD, Barrier Therapeutics, Geel, Belgium; Geert Cauwenbergh,PhD, Barrier Therapeutics, Geel, Belgium; Fre´de´ric Vanhoutte, MD, JanssenResearch Foundation, Beerse, Belgium; Lieve Vandeplassche, PhD, Barrier Therapeutics, Geel, Belgium Introduction: …
November 21st, 2006, by Digital Davo | accutane
Thanks to Rick for continuing to share his experiences in taking accutane long term at low dosage.
As he mentions in his recent message, he first posted some comments 5 years ago - `Rosacea: dramatic results with low dose accutane’. Now he has posted a new message to the group - `An update – 5+ years on low-dose accutane’.
Rick decided to experiment and stop …
September 26th, 2006, by Digital Davo | accutane, rhinophyma
If you are suffering from early stage rhinophyma you may like to consider accutane. There are some good, recently published articles that focus on rosacea and low-dose accutane. It is more difficult to find studies that specificially address treating rhinophyma with accutane.
Unfortunately doctors are finding it harder and harder to prescribe accutane. The wikipedia page on iPledge (the mandatory distribution program in the United States for isotretinoin) …
March 24th, 2006, by Digital Davo | accutane
Oral R115866 in patients with moderate to severe plaque-type psoriasis: Safety evaluation from a phase IIA trialPeter van de Kerkhof, MD, PhD, University Hospital Nijmegen, Princeton, NJ,United States; Joahan Mertens, Barrier Therapeutics, Geel, Belgium; PeterSteijlen, MD, PhD, University Hospital Maastricht, Maastricht, NetherlandsR115866 is a second-generation retinoic acid metabolism-blocking Agent (RAMBA), which has been shown to generate retinoid–mimetic biologic effects …
|
|
|
|
|
|